Symrise and Probi have expanded a joint research and development agreement for "new product solutions in the areas of food and beverages, cosmetics, dietary supplements and pharmaceuticals." The program will initially focus on oral care applications.
To date, Probi has developed gut and immune health probiotics and, with this new agreement, will expand into oral care and other areas.
Symrise currently holds a 14.97% minority share of Probi and may increase this stake in the future. This total expands an existing minority stake.
“For Symrise the agreement with Probi is a logical step which, going forward, allows us to meet the growing demand for functional consumer health products even better," said Heinz-Jürgen Bertram, CEO of Symrise AG. "Both in established markets as well as emerging markets, consumers become more and more sensitive to healthy nutrition and a balanced way of life. The highly complementary competencies and strategic innovation agendas of Probi and Symrise will allow us to support our joint customers in their development and marketing efforts, and to grow at an accelerated pace."
“The globally recognized know-how of Symrise in sensory, active ingredients and applications combined with Probi’s long-standing and proprietary expertise in patented probiotics will allow us to develop new consumer products with real health benefits and sensory profiles without compromises,” said Michael Oredsson, CEO of Probi AB.